Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Status: Enrolling
Updated:  12/31/1969
Research site
mi
from
San Juan,
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Status: Enrolling
Updated: 12/31/1969
Research site
mi
from
San Juan,
Click here to add this to my saved trials
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Miami VA Healthcare System, Miami, FL
mi
from
Miami, FL
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
VA Ann Arbor Healthcare System, Ann Arbor, MI
mi
from
Ann Arbor, MI
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
VA Ann Arbor Healthcare System, Ann Arbor, MI
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
mi
from
Omaha, NE
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
mi
from
Omaha, NE
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
South Texas Health Care System, San Antonio, TX
mi
from
San Antonio, TX
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
South Texas Health Care System, San Antonio, TX
mi
from
San Antonio, TX
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
VA Salt Lake City Health Care System, Salt Lake City, UT
mi
from
Salt Lake City, UT
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
VA Salt Lake City Health Care System, Salt Lake City, UT
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Iowa City VA Health Care System, Iowa City, IA
mi
from
Iowa City, IA
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Iowa City VA Health Care System, Iowa City, IA
mi
from
Iowa City, IA
Click here to add this to my saved trials
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
MENVEO® Pregnancy Registry: an Observational Study on the Safety of MENVEO Exposure in Pregnant Women and Their Offspring
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wilmington, NC
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
MENVEO® Pregnancy Registry: an Observational Study on the Safety of MENVEO Exposure in Pregnant Women and Their Offspring
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)
Status: Enrolling
Updated:  12/31/1969
University of Maryland, R Adams Cowley Shock Trauma Center
mi
from
Baltimore, MD
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)
Status: Enrolling
Updated: 12/31/1969
University of Maryland, R Adams Cowley Shock Trauma Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients
MT2013-37R: Voriconazole Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Patients
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients
MT2013-37R: Voriconazole Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Patients
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC (Research Site)
mi
from
Chandler, AZ
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC (Research Site)
mi
from
Chandler, AZ
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Trials, LLC.
mi
from
Paramount, CA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Trials, LLC.
mi
from
Paramount, CA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
California Research Foundation
mi
from
San Diego, CA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
California Research Foundation
mi
from
San Diego, CA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Bayview Research Group
mi
from
Valley Village, CA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Bayview Research Group
mi
from
Valley Village, CA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
USF Health South Tampa Center for Advanced Healthcare
mi
from
Tampa, FL
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
USF Health South Tampa Center for Advanced Healthcare
mi
from
Tampa, FL
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
USF Health
mi
from
Tampa, FL
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
USF Health
mi
from
Tampa, FL
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
North Georgia Research Clinical Center
mi
from
Dalton, GA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
North Georgia Research Clinical Center
mi
from
Dalton, GA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Pediatrics & Adolescent Medicine, Pa
mi
from
Marietta, GA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Pediatrics & Adolescent Medicine, Pa
mi
from
Marietta, GA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Augusta, KA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Augusta, KA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Kentucky Pediatric/ Adult Research
mi
from
Bardstown, KY
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Kentucky Pediatric/ Adult Research
mi
from
Bardstown, KY
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Brownsboro Park Pediatrics
mi
from
Louisville, KY
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Brownsboro Park Pediatrics
mi
from
Louisville, KY
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Bluegrass Clinical Research
mi
from
Louisville, KY
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Bluegrass Clinical Research
mi
from
Louisville, KY
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Southwestern Medical Clinic, Lakeland HealthCare Affiliate
mi
from
Stevensville, MI
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Southwestern Medical Clinic, Lakeland HealthCare Affiliate
mi
from
Stevensville, MI
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC
mi
from
Fremont, NE
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC
mi
from
Fremont, NE
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Midwest Children'S Health Research Institute
mi
from
Lincoln, NE
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Midwest Children'S Health Research Institute
mi
from
Lincoln, NE
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Nevada
mi
from
Henderson, NV
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Nevada
mi
from
Henderson, NV
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Ohio Pediatric Research Association, Inc
mi
from
Dayton, OH
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Ohio Pediatric Research Association, Inc
mi
from
Dayton, OH
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Ohio Pediatrics, Inc
mi
from
Dayton, OH
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Ohio Pediatrics, Inc
mi
from
Dayton, OH
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
West Houston Clinical Research Service (WHCRS)
mi
from
Houston, TX
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
West Houston Clinical Research Service (WHCRS)
mi
from
Houston, TX
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
J. Lewis Research Inc.-Foothill Family Clinic
mi
from
Salt Lake City, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
J. Lewis Research Inc.-Foothill Family Clinic
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
J. Lewis Research, Inc. / Foothill Family Clinic South
mi
from
Salt Lake City, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
J. Lewis Research, Inc. / Foothill Family Clinic South
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
J. Lewis Research, Inc. / Jordan River Family Medicine
mi
from
South Jordan, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
J. Lewis Research, Inc. / Jordan River Family Medicine
mi
from
South Jordan, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
mi
from
West Jordan, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
mi
from
West Jordan, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
The Vancouver Clinic, Inc, PS
mi
from
Vancouver, WA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
The Vancouver Clinic, Inc, PS
mi
from
Vancouver, WA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Monroe Clinic
mi
from
Monroe, WI
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Monroe Clinic
mi
from
Monroe, WI
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Pediatrics and Adolescent Medicine
mi
from
Woodstock, GA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Pediatrics and Adolescent Medicine
mi
from
Woodstock, GA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Ordinace praktickeho lekare pro deti a dorost
mi
from
Holice,
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Ordinace praktickeho lekare pro deti a dorost
mi
from
Holice,
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Research and Education Association for Clinical Health, Inc.
mi
from
Monroe, WI
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Research and Education Association for Clinical Health, Inc.
mi
from
Monroe, WI
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
U of L Pediatrics: Downtown
mi
from
Louisville, KY
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
U of L Pediatrics: Downtown
mi
from
Louisville, KY
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Dr. Shelly David Senders, MD Inc. dba Senders Pediatrics
mi
from
Cleveland, OH
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Dr. Shelly David Senders, MD Inc. dba Senders Pediatrics
mi
from
Cleveland, OH
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
BB Holdings, LLC., dba Jean Brown Research
mi
from
Salt Lake City, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
BB Holdings, LLC., dba Jean Brown Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Creighton University Pediatric Infectious Diseases
mi
from
Omaha, NE
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Creighton University Pediatric Infectious Diseases
mi
from
Omaha, NE
Click here to add this to my saved trials